Eledon Pharmaceuticals, Inc. (ELDN): R&D Expense
$66.27M
Year ended 2025-12-31
$67.89M
Trailing 12 months to 2026-06-30
+34.8%
3-year compound annual growth
+61.0%
5-year compound annual growth
+7.3%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $66.27M | +27.5% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $51.96M | +71.4% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $30.31M | +11.9% | 2025-08-14, From 2023-01-01 |
| 2022-12-31 | $27.08M | +14.1% | 2024-08-19, From 2022-01-01 |
| 2021-12-31 | $23.73M | +287.1% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $6.13M | -24.6% | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | $8.13M | +19.2% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $6.82M | +237.1% | 2020-03-17, From 2018-01-01 |
| 2017-12-31 | $2.02M | -36.6% | 2019-03-28, From 2017-01-01 |
| 2016-12-31 | $3.19M | -90.2% | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | $32.64M | +123.9% | 2017-03-03, From 2015-01-01 |
| 2014-12-31 | $14.58M | +19.5% | 2017-03-03, From 2014-01-01 |
| 2013-12-31 | $12.20M | +65.5% | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | $7.37M | n/a | 2015-03-26, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $66.27M | +27.5% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $70.09M | +117.5% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $46.71M | +225.8% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.70M | +13.9% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
| PepGen Inc. (PEPG) | 2025-12-31 | $71.04M | -7.1% |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $1.63M | n/a |
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $25.67M | -55.1% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $13.42M | +38.3% |
Compare ELDN, CRBP, CLYM, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗